Osteogenesis imperfecta (OI) type I is the mildest form of heritable bone fragility resulting from mutations within the COLlAl gene. We studied fibroblasts established from a child with 01 type I and demonstrated underproduction of al (I) collagen chains and al (I) mRNA. Indirect RNase protection suggested two species of al (I) mRNA, one of which was not collinear with fully spliced al (I) mRNA. The noncollinear population was confined to the nuclear compartment of the cell, and contained the entire sequence of intron 26 and a G -* A transition in the first position of the intron donor site. The G --A transition was also identified in the genomic DNA. The retained intron contained an in-frame stop codon and introduced an out-of-frame insertion within the collagen mRNA producing stop codons downstream of the insertion. These changes probably account for the failure of the mutant RNA to appear in the cytoplasm. Unlike other splice site mutations within collagen mRNA that resulted in exon skipping and a truncated but inframe RNA transcript, this mutation did not result in production of a defective collagen proal (I) chain. Instead, the mild nature of the disease in this case reflects failure to process the defective mRNA and thus the absence ofa protein product from the mutant allele. (J. Clin. Invest.
Introduction
Osteogenesis imperfecta (01)1 is a heritable disorder that results in bone fragility. Identification of mutations within the COLlA 1 and COL1A2 genes that encode the chains of type I collagen has begun to provide a detailed understanding of the structural requirements for the type I collagen molecule ( 1, 2) . Mutations that disrupt the triple-helical configuration of colla-1. Abbreviations used in this paper: nt, nucleotide; 01, osteogenesis imperfecta.
gen, including substitutions for glycine in the gly-x-y triplet (3) , partial gene deletions (4) , and exon skipping (5) , pro- duce, depending on the location of the mutation, a range of disease severity that extends from lethal (01 type II) to severely deforming (01 type III) to mildly deforming (01 type IV) (6) .
In 01 type I fractures are usually limited to the prepubertal years and are not associated with bone deformity. At times the fracture frequency is not recognized as a distinct abnormality and the disorder only comes to medical attention when earlyonset osteoporosis develops in adult family members. Thus, mild forms of 01 and "familial osteoporosis" often coexist, in part because the underlying pathogenesis may be similar. For mutations in the a I (I) chain (COLlA 1), there appears to be a positional effect in which those at the COOH terminus are more likely to result in severe disease than those at the NH2 terminus (7) . In fact, substitutions for glycine have been identified near the NH2-terminal end ofthe triple helix that result in nondeforming bone disease (type I 01) and heritable osteoporosis (8) . Mutations within the a2 (I) chain (COL I A2 gene) that produce mild 01 or osteoporosis (9) do not always occur at the NH2-terminal end of the chain (10) .
The most common mechanism for 01 type I appears to be decreased synthesis of normal type I collagen molecules. The synthesis ofproa 1 ( 1 ) collagen chains ( 11 ) and the steady-state level of a 1(I) mRNA appears to be reduced by -50% (12, 13) , suggesting that one of the two COLlA 1 alleles is "null."
We previously showed that dermal fibroblasts from some individuals with type I 01 contain normal or elevated amounts of a I (I) mRNA in the nucleus ( 14) . Furthermore, a novel species of a 1(I) collagen mRNA present in the nuclear compartment of cells from one such child was not collinear with a cDNA probe ( 15) . In this paper we show that a mutation within a splice donor site results in inclusion of the entire succeeding intron in the mature mRNA that accumulates in the nuclear compartment. Apparently because no abnormal proa I(I) chains are synthesized from the mutant allele, the clinical phenotype of this child is mild.
Methods
Description ofpatient. CF was a 13-yr-old female at the time of the dermal biopsy (cell line 053). She had been followed at the Newington Childrens Hospital (NCH) between 10 and 15 yr of age. She had sustained seven fractures before her first NCH visit, all of which healed without deformity. Subsequently, the fracture rate diminished and her primary problems were ligament strains and knee discomfort secondary to patellar subluxation. Her height was at the 50-75 percentile. She had blue sclera, ligamentous laxity, a mild thoracic scoliosis ( < 10%), and normal dentition. Her current age is 28 yr, and she and her family, including an affected brother, have been lost to follow-up.
Cell culture. A fibroblast strain was derived from a skin explant taken from the inner aspect of the upper arm. Fibroblasts were maintained as previously described ( 12) . Confluent cultures were harvested for protein or RNA after 48 h in fresh culture media supplemented daily with 25 ,ug/ml ascorbic acid.
tracted from the confluent fibroblasts cell layer using the SDS proteinase K method (18 ) . The nuclear and cytoplasmic compartments of the cells were isolated as previously described ( 14) . Briefly, confluent fibroblast cultures ( 12-100-mm petri plates) were scraped from the plate in 10 ml ofcold PBS, centrifuged, and resuspended in 15 ml of lysis buffer (10 mM Tris, pH 7.5, 10 mM KCI, and 1.5 mM MgCl2) containing 0.25% Triton X-100. The pellet was disrupted by dounce homogenization with a tight-fitting pestle. The suspension was centrifuged for 10 min at 2,200 g and the supernatant was transferred to a 30-ml corex tube (cytoplasmic extract) containing 2.0 ml ofa lOX extraction buffer (10% SDS, 0.10 M Tris, pH 7.5, 0.05 M EDTA, and 500 Mg/ml of proteinase K). The nuclear pellet was reextracted a second time in 5 ml of lysis buffer with Dounce homogenization. After centrifugation, the supernatant was combined with the first extract, producing a final concentration of the extraction buffer of lx. The nuclear pellet was extracted in 15 ml of lx extraction buffer. Subsequent steps of RNA isolation followed the SDS proteinase K protocol ( 18) .
DNA was harvested from cultured fibroblasts in 1X extraction buffer containing 100 Mg/ml of proteinase K. The digest was extracted sequentially in phenol/chloroform and chloroform and adjusted to 0.3 M NaOAc. Two to three volumes of ethanol was layered over the extract, and the DNA was spooled from the interface, washed in 70%
ethanol, dried, and resuspended in water. RNA analysis. The relative content of al (I) and a2(I) mRNA in the nuclear and cytoplasmic compartments was assessed by dot hybridization as previously described ( 14) . The filters were hybridized with al (I)-and a22(I)-specific cDNA probes (HF404 [19] and HF32 [20] ) after labeling by the random primer method (21 ) . The relative intensity of hybridization was quantitated in a Betascope G03 (Betagen, Waltham, MA) from the slope of the dilution curve of patient and control RNA.
The method for indirect RNase protection of nuclear and cytoplasmic RNA using single-stranded (SS) antisense cDNA to a I ( 1 ) mRNA has been previously described (15 The mixture was heated at 650C for 3 min, cooled, adjusted to contain 500MgM dNTPs, and 500 U ofMoloney murine leukemia virus (M-MLV) reverse transcriptase. The incubation lasted for 1 h at 370C and was followed by phenol/chloroform extraction and ethanol precipitation. The sample was dissolved in 20 ,l water and 1 Ml was used for PCR amplification. In the case of genomic DNA, 1 Mg of DNA was used in the PCR reaction. The oligonucleotide pairs for each set of amplifications are given in Table I .
The PCR mixture contained 50 mM KCl, 10mM Tris, pH 8.3, 1.5 mM MgCl2, 0.01% gelatin, and 2.5 U AmpliTaq (Perkin Elmer Corp., Norwalk, CT) in a final reaction volume of 84 Ml. The mixture was heated to 940C for 5 min, after which the 16 Ml containing 200 gM dNTPs (hot start [24] ) was added and the sample was cycled 25 times with denaturation at 940C for 1 min, hybridization at 620C for 1 min, and polymerization at 720C for 1 min in a DNA thermal cycler(Perkin Elmer-Corp.). The products were extracted in phenol/chloroform and 1:10 of the original reaction volume was applied to a 5% polyacrylamide TBE mini-gel.
For direct DNA sequencing of PCR products, we used the dsDNA Cycle Sequencing System (GIBCO BRL). PCR products were cloned either with G-tailing into C-tailed pUC9 vector (Pharmacia Fine Chemicals, Piscataway, NJ) or by blunt end cloning into Sma site pBSII-SK+. For sequencing of the cloned DNA, we used the Sequenase Reagent Kit (no. 70750; United States Biochem. Corp., Cleveland, OH).
Results
Total collagen synthesis by the fibroblasts derived from the patient (Table II) was 4.0% oftotal protein synthesis. For comparison, three cell strains derived from patients with severe forms of the disease are shown. We have observed significant variation in the rate and percentage of collagen synthesis in part dependent on the age ofthe donor. The range of synthesis in non-OI control cells is 5-7% (5) . In most of the cell strains obtained from patients with 01 type I, a reduced rate of total collagen synthesis is observed.
The relative proportion of type I and type III collagen was determined on pepsin-treated radiolabeled protein extracts of the medium and cell layer (Fig. 1) . The ratio was elevated to 0.38 and 0.45 in two experiments (control patients range from 0.15 to 0.25). Because an equal amount of total collagen is loaded into each electrophoresis lane, the elevation in the collagen type III-to-I ratio reflects underproduction of type I collagen. The electrophoretic mobilities of the a I(I) and a2(I) chains from the patient sample were identical to those of the control sample.
The relative content of a 1(I) and a2 (I) mRNA was determined by dot blot hybridization and compared with the ratio of control cells (Fig. 2) . The slope of the line ofdot density when the filter was hybridized to an a 1(I) or a2 (I) cDNA probe was compared with the slope of a control RNA applied to the same filter. In this assay, the alI (I)/a2(I) mRNA ratio ofthe control is normalized to 1. When the slope of the al (I) and a2(I) mRNA derived from cell strain 053 was compared with the standard (std), the al (I)/std was 0.30 and the a2 (I)/std was 1.19, making the alI (I)/a2(I) ratio of the patient 0.25. Thus, the amount of a 1(I) mRNA present in the total cellular RNA was reduced to less than halfofthe control. Because the control Analysis of this patient and other cell lines with 01 type 1 indicated that the a I (I)/a2 (I) collagen mRNA ratio extracted from isolated nuclei approximated or exceeded 2:1 in contrast to the low ratio from cytoplasmic compartment ( 14) . This observation suggested a defect in a 1(I) mRNA transport similar to that observed in splicing defects associated with f3-thalassemia (25, 26 ). An indirect RNase protection was developed to detect insertions within collagen mRNA ( 15 ) . It relies on protection of the mature mRNA with a single-stranded antisense cDNA. The protected or cleaved RNA is detected by Northern hybridization of the RNase-digested products. Nuclear and cytoplasmic RNA was protected with a 1.8-kb cDNA fragment derived from HF404 that encodes exons (Fig. 3) . In RNA from cell strain 053, the expected 1.8-nucleotide (nt) band and two smaller bands (1.4 and 0.4 nt) were visible in nuclear RNA. Only the fully protected band was present in the cytoplasmic RNA and was similar in size to RNA extracted from normal cells.
To characterize the abnormal RNA species, nuclear RNA was reverse transcribed and then PCR amplified in segments to span the region encoded by HF404 (Fig. 4) . Of the five PCR primer sets used (Table I) , two (sets 3 and 4) produced a second higher molecular weight ( -150 bp larger) band from the patient but not the control RNA. A third band well above the 1.3-kb marker was also unique to these oligonucleotide sets and probably represents a heterodimer produced when two complementary strands of different lengths hybridized during Fig. 5 A) in the larger species. Furthermore, the expected first position donor site G was replaced by an A. This mutation was confirmed when the corresponding region of the genomic DNA was isolated by PCR and found to be present in -50% of the clones sequenced (Fig. 5 B) .
The cloned reverse transcriptase PCR fragments encompassing exons 25-28 derived from oligonucleotide set 3 were used to generate a radiolabeled antisense cRNA probes complementary to the retained intron and the normally spliced transcript. These probes were hybridized to nuclear and cytoplasmic RNA derived from the patient and control cell strain ( 6). The probe containing the included intron protected the predicted 442-nt fragment in the nuclear (Fig. 6 A, lanes 4 and  6) but not the cytoplasmic compartment (Fig. 6 A, lanes 3 and  5) of the patient RNA. No evidence of the 442-nt band was present in the control RNA (Fig. 6 A, lanes 7 and 8) . The RNA encoded by the normal COLlA 1 allele from the patient as well as all the RNA from the control cell line did not protect the intron 26-containing probe. Instead the probe was cleaved producing two fragments (209 and 90 nt) collinear with the flanking exons. The cRNA probe derived from the normally spliced allele was protected equally well by total fibroblast RNA from the patient (Fig. 6 B, lane 6) and control ( Fig. 6 B, lane 5), indicating that exon skipping was not occurring to a significant degree as a result of the donor site mutation (27) . The intensity of the normally spliced transcript in the patient total RNA extract is significantly less than the control, confirming the low amount of normal a 1 (I) mRNA that is present in this cell strain.
Discussion
The fibroblasts derived from this patient had a G --A transition at position + 1 A frame shift or premature stop codon that results from a mutation within an exon would be expected to produce the same effect as a retained intron, although an example of this type of mutation has not been reported. All of the defined mutations of COL I A 1 or COL I A2 that induced a frame shift did not result in a premature stop codon before the terminal exon (30) (31) (32) (33) . Low levels of al (I) mRNA (based on reversed ratio of a 1 / a2 mRNA ratio of 1:2) were observed with a frame shift in exon 51 that inactivated the authentic translation termination codon and extended the translated product to the first polyadenylation signal (34). A potential mechanism for the low a I (I) mRNA seen in this case is an indirect effect on splicing secondary to the altered transcriptional termination signal (35) .
In fibrillar collagen genes all the exons that encode the triple-helical portion of the a chain are in-frame cassettes of the Gly X-Y triplet starting with the first G of the glycine codon and ending with the last nucleotide of the Y position amino acid. The collagen mutations that cause abnormalities of splicing were initially discovered because ofsynthesis ofshortened a chains. The shortened chain resulted from exon skipping due to a mutation in either an intron donor or acceptor site (Table  III) . These mutations can result in more severe forms of 01 because the shortened RNA transcripts are in frame, are transported to the cytoplasm, and are translated into a functional although truncated a chain. The shortened a chain is incorporated into a trimeric molecule that interferes with secretion, proteolytic processing, and fibrillogenesis, thus accounting for the strong dominant nature of mutations of structural macromolecules (36) .
An explanation for why a similar mutation in a donor site results in exon skipping in the cases cited above and intron retention in our case comes from the model of exon definition developed by Robberson et al. (37) and Talerico and Berget (38) . In this model, the first step is the binding ofU2 RNA to a potential intron acceptor site followed by the second step, in which U I RNA and specific proteins identify and bind to the strongest adjacent downstream donor site (39) . This process defines the exons and initiates the splicing machinery to excise the intervening intron sequence. If U1RNA identifies an adequate donor within 300 bases (the upper limit in size for internal exons [40] ), then an exon is defined (Fig. 7 a) and the intervening introns are spliced. With a mutant donor site, ifthe intron is large and U 1 RNA does not detect an adequate downstream donor site within 300 bases, no acceptable exon is defined, so that it and its flanking introns are spliced out of the mature message (exon skipping; Fig. 7 b) . However, if the intron is small, then U 1RNA will identify the authentic donor site ofthe subsequent downstream intron. This defines the two exons and the included intron as an acceptable "exon." Thus, the entire intron is retained in the mature RNA (intron retention; Fig. 7 c) . This model accounts for why a mutant donor site can result in either exon skipping or intron retention and also predicts that all intron acceptor site mutations will result in exon skipping, because the defining process to identify an exon is initiated from the acceptor site.
Approximately halfofthe introns within the a I (I) gene are < 150 bp, making the risk for a donor site mutation leading to a retained intron a common possibility. There are 25 exon/intron / exon combinations that are < 300 bp, the size limit for an acceptable exon if the donor site of the included intron was inactivated. 17 ofthe candidate sites would induce a frame shift mutation, while 5 of the in-frame introns contain an in-frame stop codon. The phenotype of a patient harboring a mutation that introduces a frame shift-producing or stop codon-con- Review of published data of collagen splicing mutations is consistent with the exon definition model, with one possible exception (Table III) . All acceptor mutations resulted in exon skipping (49, 50) , as did donor mutations where the exon/intron/exon size (scanning domain) was > 300 nt (5, (45) (46) (47) (48) . In a number ofthese cases (49) the mRNA product ofthe mutant allele was lower than predicted by the model. It seems likely that cryptic splice sites may have been used and produced some transcripts containing frame shift mutations that were not transported to the cytoplasm. Since nuclear RNA was not examined in these cases, this possibility needs further examination.
The exon definition model may require modification to accommodate an exon 14 donor site mutation in COLlAl (50) . Here intron retention is predicted that would insert three in-frame stop codons and produce an OI type I phenotype. Instead, exon 14 was skipped and resulted in a lethal phenotype (Table III) . A potential explanation for this exception is the nature ofthe mutation. This donor site mutation was located at position + 5, which is a less highly conserved consensus base and produced either normal splicing or exon skipping. Normal splicing was decreased at elevated temperatures. This suggests that the exon-defining mechanism can be disrupted if there is weak binding of U1RNA at the mutant donor site. In those transcripts where U 1 binds the mutant site but does not result in cleavage, there is interference with splicing of the upstream intron such that the upstream intron forms a lariat with the downstream branch point resulting in exon skipping. Cooperation between branch points and donor sites in determining the extent ofexon skipping has been observed in a different context (39, 51 ) . Other factors such as strength of competing donor and acceptor splice sites and exon size also influence which splicing alternative will predominate, and may account for the heterogeneity of disease severity observed in mild to moderately deforming 01 that result from mutations that affect splicing of collagen mRNA. The exception observed in this case suggests that an included intron will only be observed when the donor site is completely inactivated and the scanning mechanism progresses to the next downstream strong donor site.
Analysis of patients with a null collagen allele has been difficult because protein data pointing to the site of a potential *1i Figure 6 . Direct RNase protection of RNA from patient and control fibroblast strains. (A) RNA was hybridized with the intron 26-containing cRNA probe derived from cloning and sequencing experiment discussed in Fig. 5 mutation are lacking. Initial characterization of nuclear RNA not only suggests potential mechanisms to account for the underproduction ofmature mRNA from the mutant allele, it provides localization of an unprocessed intron that might not be obtained from analysis oftotal RNA because ofthe enrichment of the abnormal transcript in the nuclear compartment. The difficulty of detecting null-producing mutations in cDNA derived from total RNA is illustrated by the presence of 2 abnormal of 19 sequenced cDNA transcripts of the 2.5-kb ferrochelastase mRNA (52), < 2% ofthe expected cystic fibrosis transmembrane conductance regulator transcript in bronchial epithelial cells detected by mutation specific oligonucleotide hybridization (53) , and < 5% of a frame shift-producing exon skip mutation of the 5.3-kb low density lipoprotein receptor mRNA (54) . It is likely that frame shift mutations that result from insertions or deletions within exons of COLlA 1 will also account for type I 01 but these will be hard to localize by the RNase protection techniques used in this case. PCR of fragments of nuclear mRNA enriched for the presence of the mutant transcript followed by an analysis using techniques capable of detecting a l-bp change will be required to identify such cases. Discovery ofmutations within the regulatory domains of the COL IA 1 gene that lead to reduced transcriptional activity will be an even greater challenge because the regions essential for the activity of this gene in collagen-producing tissues are not yet clearly defined (55) . These will be important abnormalities to identify because it is likely that subtle mutations that result in a partially null allele of the COLlA 1 gene may be a common cause oftype I 01 and heritable forms ofosteoporosis.
